Perrigo Company PLC
F:PIG
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Perrigo Company PLC
F:PIG
|
IE |
|
M
|
Mettler-Toledo International Inc
SWB:MTO
|
US |
|
N
|
NetApp Inc
XBER:NTA
|
US |
|
T
|
Toll Brothers Inc
LSE:0LFS
|
US |
|
S
|
SK Hynix Inc
DUS:HY9H
|
KR |
|
M
|
Mr Price Group Ltd
JSE:MRP
|
ZA |
|
S
|
Southern Co
XETRA:SOT
|
US |
|
W
|
Wabash National Corp
XBER:WA9
|
US |
|
SAP SE
LSE:0A2W
|
DE |
|
A
|
Arrow Electronics Inc
DUS:ARW
|
US |
|
V
|
Vulcan Materials Co
F:VMC
|
US |
|
Stora Enso Oyj
F:ENUN
|
FI |
Perrigo Company PLC
Perrigo Company PLC makes everyday health and wellness products that people buy without a prescription. Its portfolio includes over-the-counter medicines, vitamins and supplements, oral care items, and infant nutrition products. The company sells many of these products under store brands or retailer-owned labels, so shoppers may not see Perrigo’s name on the package even though it helped make the product. Its main customers are large drugstore chains, grocery stores, mass merchants, and other retailers that want reliable private-label products for their shelves. Perrigo also sells some branded products directly in pharmacies and other consumer channels. It makes money by manufacturing, packaging, and supplying these products, then getting paid through retail supply agreements and brand sales. Perrigo’s role is different from a typical branded consumer health company because it sits behind the scenes as a maker of everyday health products for retailers and consumers. That gives it a strong position in private-label health care, where buyers care about consistent quality, broad availability, and price. The company’s business depends on making repeat-use products that retailers can reorder regularly and consumers can trust for routine self-care.
Perrigo Company PLC makes everyday health and wellness products that people buy without a prescription. Its portfolio includes over-the-counter medicines, vitamins and supplements, oral care items, and infant nutrition products. The company sells many of these products under store brands or retailer-owned labels, so shoppers may not see Perrigo’s name on the package even though it helped make the product.
Its main customers are large drugstore chains, grocery stores, mass merchants, and other retailers that want reliable private-label products for their shelves. Perrigo also sells some branded products directly in pharmacies and other consumer channels. It makes money by manufacturing, packaging, and supplying these products, then getting paid through retail supply agreements and brand sales.
Perrigo’s role is different from a typical branded consumer health company because it sits behind the scenes as a maker of everyday health products for retailers and consumers. That gives it a strong position in private-label health care, where buyers care about consistent quality, broad availability, and price. The company’s business depends on making repeat-use products that retailers can reorder regularly and consumers can trust for routine self-care.
Guidance reaffirmed: Perrigo kept its 2026 outlook unchanged, saying results should be weighted to the second half as category demand stabilizes, prior-year manufacturing headwinds roll off, and cost savings ramp.
Sales pressure: First-quarter sales were hit by softer cough and cold demand, retailer destocking, and weak European consumption, but management said these headwinds look transitory.
Share gains: The company said its Three-S plan is working, with broad market share gains in U.S. store brand OTC and stronger branded performance in Europe, especially in seasonal brands.
Cost actions: Perrigo completed the Dermacosmetics divestiture and said proceeds will support debt reduction, while its cost-saving program is on track for $60 million to $80 million in 2026.
Infant Formula: The strategic review of Infant Formula is still ongoing, with management also pointing to improved service levels, supply reliability, and some recovery in the quarter.
Pricing watch: Management said inflation linked to Middle East developments has been moderate so far, but it is actively considering pricing actions if needed.
